Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1990 2
1992 9
1993 8
1994 5
1995 4
1996 9
1997 7
1998 4
1999 6
2000 8
2001 1
2002 3
2003 6
2004 3
2005 3
2006 8
2007 8
2008 9
2009 4
2010 8
2011 9
2012 9
2013 6
2014 8
2015 6
2016 9
2017 6
2018 10
2019 9
2020 8
2021 2
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

192 results
Results by year
Filters applied: . Clear all
Page 1
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Pfisterer J, et al. Among authors: zeimet ag. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Lancet Oncol. 2020. PMID: 32305099 Clinical Trial.
Ovarian Cancer Stem Cell Heterogeneity.
Hatina J, Boesch M, Sopper S, Kripnerova M, Wolf D, Reimer D, Marth C, Zeimet AG. Hatina J, et al. Among authors: zeimet ag. Adv Exp Med Biol. 2019;1139:201-221. doi: 10.1007/978-3-030-14366-4_12. Adv Exp Med Biol. 2019. PMID: 31134503 Review.
Ovarian cancer stem cells.
Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, Wiedemair AM, Rumpold H, Untergasser G, Concin N, Hofstetter G, Muller-Holzner E, Fiegl H, Marth C, Wolf D, Pesta M, Hatina J. Zeimet AG, et al. Neoplasma. 2012;59(6):747-55. doi: 10.4149/neo_2012_094. Neoplasma. 2012. PMID: 22862176 Review.
The miR-34 family and its clinical significance in ovarian cancer.
Welponer H, Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Marth C, Hackl H, Fiegl H, Zeimet AG. Welponer H, et al. Among authors: zeimet ag. J Cancer. 2020 Jan 13;11(6):1446-1456. doi: 10.7150/jca.33831. eCollection 2020. J Cancer. 2020. PMID: 32047551 Free PMC article.
Hopes and failures in front-line ovarian cancer therapy.
Tsibulak I, Zeimet AG, Marth C. Tsibulak I, et al. Among authors: zeimet ag. Crit Rev Oncol Hematol. 2019 Nov;143:14-19. doi: 10.1016/j.critrevonc.2019.08.002. Epub 2019 Aug 14. Crit Rev Oncol Hematol. 2019. PMID: 31449982 Free article. Review.
Clinical trials in recurrent ovarian cancer.
Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup. Friedlander M, et al. Among authors: zeimet a. Int J Gynecol Cancer. 2011 May;21(4):771-5. doi: 10.1097/IGC.0b013e31821bb8aa. Int J Gynecol Cancer. 2011. PMID: 21543939 Review.
Immunotherapy in ovarian cancer: fake news or the real deal?
Marth C, Wieser V, Tsibulak I, Zeimet AG. Marth C, et al. Among authors: zeimet ag. Int J Gynecol Cancer. 2019 Jan;29(1):201-211. doi: 10.1136/ijgc-2018-000011. Int J Gynecol Cancer. 2019. PMID: 30640705 Review.
192 results